Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 5/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 5/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 3/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2232584 | 0.90 | DRD2 (0.33) | ACEBCHEACHEDRD2NR1I3 | |
| SCHEMBL2234784 | 0.90 | BCHE (0.32) | ACEBCHEACHEDRD2KEAP1 | |
| SCHEMBL2235746 | 0.90 | DRD2 (0.34) | ACEBCHEACHEDRD2NR1I3 | |
| SCHEMBL2237504 | 0.89 | ACE (0.38) | ACEBCHEACHEDRD2NR1I3 | |
| SCHEMBL2236732 | 0.89 | ACE (0.38) | ACEBCHEACHEDRD2NR1I3 | |
| SCHEMBL2235860 | 0.88 | PDK1 (0.32) | ACEBCHEACHEDRD2NR1I3 | |
| SCHEMBL2383494 | 0.88 | DRD2 (0.32) | ACEBCHEACHEDRD2 | |
| SCHEMBL2235898 | 0.77 | MEN1 (0.40) | NPC1L1ACE | |
| SCHEMBL2235104 | 0.72 | ACE (0.41) | ACEDRD2NR1I3 | |
| SCHEMBL2233419 | 0.70 | ACE (0.41) | ACEDRD2NR1I3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2361910-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | NPC1L1 4612/4885ACE 473/4885BCHE 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.